Can you take Anakinra with Cervarix?

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Dehydration.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a major potential interaction with Fever.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Hypotension.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

Anakinra has a moderate potential interaction with Immunodeficiency.

Anakinra has been associated with an increased incidence of serious infections in clinical trials in rheumatoid arthritis (RA). RA therapy should be discontinued if a patient develops a serious infection. In neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA) patients treated with anakinra, the risk of a disease flare when discontinuing this drug should be weighed against the potential risk of continued therapy. Anakinra should not be started in patients with active infections. Safety and efficacy have not been evaluated in immunosuppressed patients or in patients with chronic infections; caution is recommended when using anakinra in these patients.

Drugs that affect the immune system by blocking tumor necrosis factor have been associated with an increased risk of reactivation of latent tuberculosis; it is possible that taking drugs that block interleukin-1 (such as anakinra) increases the risk of tuberculosis or other atypical or opportunistic infections. The current US CDC guidelines should be followed both to evaluate for and to treat possible latent tuberculosis before starting therapy with anakinra.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Immunodeficiency.

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

The human papillomavirus vaccine in Cervarix has a major potential interaction with Infection.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

Anakinra has a moderate potential interaction with Infection.

Anakinra has been associated with an increased incidence of serious infections in clinical trials in rheumatoid arthritis (RA). RA therapy should be discontinued if a patient develops a serious infection. In neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA) patients treated with anakinra, the risk of a disease flare when discontinuing this drug should be weighed against the potential risk of continued therapy. Anakinra should not be started in patients with active infections. Safety and efficacy have not been evaluated in immunosuppressed patients or in patients with chronic infections; caution is recommended when using anakinra in these patients.

Drugs that affect the immune system by blocking tumor necrosis factor have been associated with an increased risk of reactivation of latent tuberculosis; it is possible that taking drugs that block interleukin-1 (such as anakinra) increases the risk of tuberculosis or other atypical or opportunistic infections. The current US CDC guidelines should be followed both to evaluate for and to treat possible latent tuberculosis before starting therapy with anakinra.

Anakinra has a moderate potential interaction with Liver Disease.

No formal studies have been conducted examining the pharmacokinetics of anakinra administered subcutaneously in patients with hepatic dysfunction. Caution is recommended when using anakinra in these patients.

Anakinra has a moderate potential interaction with Neutropenia.

The use of anakinra has been associated with a decrease in neutrophil counts. Neutrophil counts should be assessed prior to initiating therapy and while receiving therapy, monthly for 3 months and thereafter quarterly for up to 1 year.

Anakinra has a moderate potential interaction with Renal Dysfunction.

Anakinra is substantially excreted by the kidney. The risk of toxic reactions to this drug may be greater in patients with impaired renal function. Administration of the prescribed dose every other day should be considered for patients who have severe renal dysfunction or end-stage renal disease (defined as CrCl less than 30 mL/min [as estimated from serum creatinine levels]). Caution should be exercised when using anakinra in these patients.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Syncope.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

Anakinra has a moderate potential interaction with Tuberculosis, Latent.

Anakinra has been associated with an increased incidence of serious infections in clinical trials in rheumatoid arthritis (RA). RA therapy should be discontinued if a patient develops a serious infection. In neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA) patients treated with anakinra, the risk of a disease flare when discontinuing this drug should be weighed against the potential risk of continued therapy. Anakinra should not be started in patients with active infections. Safety and efficacy have not been evaluated in immunosuppressed patients or in patients with chronic infections; caution is recommended when using anakinra in these patients.

Drugs that affect the immune system by blocking tumor necrosis factor have been associated with an increased risk of reactivation of latent tuberculosis; it is possible that taking drugs that block interleukin-1 (such as anakinra) increases the risk of tuberculosis or other atypical or opportunistic infections. The current US CDC guidelines should be followed both to evaluate for and to treat possible latent tuberculosis before starting therapy with anakinra.